Last reviewed · How we verify

Hualan Biological Engineering, Inc. — Portfolio Competitive Intelligence Brief

Hualan Biological Engineering, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Influenza split vaccine Influenza split vaccine phase 3 Inactivated split influenza vaccine Immunology
A+C Meningococcal Polysaccharide Vaccine A+C Meningococcal Polysaccharide Vaccine phase 3 Polysaccharide vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Astellas Pharma Inc · 1 shared drug class
  2. Celgene · 1 shared drug class
  3. Fakultas Kedokteran Universitas Indonesia · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Korea University Guro Hospital · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. Shanghai Institute Of Biological Products · 1 shared drug class
  8. St. Petersburg Research Institute of Vaccines and Sera · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hualan Biological Engineering, Inc.:

Cite this brief

Drug Landscape (2026). Hualan Biological Engineering, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hualan-biological-engineering-inc. Accessed 2026-05-16.

Related